Taxonomy

CMTA Appoints Katherine Forsey Chief Research Officer

(GLENOLDEN, Pa. – June 2, 2022) The Charcot-Marie-Tooth Association today

New Data Shows Sustained Benefit with PXT3003 in Patients with CMT1A

New Data from the Open-Label PLEO-CMT-FU Trial Shows Sustained Benefit

Orphan Drug Designation for TSHA-120 for Treatment of Giant Axonal Neuropathy (GAN)

Taysha Gene Therapies Receives Orphan Drug Designation from the European

Participants Needed for SORD Clinical Trial

Participants Needed for SORD Clinical Trial Plans are underway for

The CMTA Earns a Perfect Rating From Charity Navigator

The Charcot-Marie-Tooth Association Earns a Perfect Rating From Charity Navigator

Finding Your CMT Gene

Finding Your CMT Gene – The Distant Cousin Project The

2021 STAR Accomplishments

With our community’s help, the CMTA has invested over $17.5

Applied Therapeutics Announces Initiation of Registrational Phase 2/3 Study of AT-007 in SORD Deficiency

Applied Therapeutics Announces Initiation of Registrational Phase 2/3 Study of

CMTA Seed Money Draws NIH Support For Type 2 Gene Editing, Neurofilament Projects

CMTA Seed Money Draws NIH Support For Type 2 Gene

CMTA-STAR Awards $354,826 for CMT Clinical Trial

CMTA-STAR Awards $354,826 for CMT Clinical Trial (Glenolden, PA, December